Detect early.
Live fully.
A clinical diagnostics company advancing multi-biomarker blood tests for women’s health, starting with ovarian cancer.
Powered by a proprietary glycoproteomics platform.
Our tests detect multiple biomarkers at once.
Most tumor markers ignore the sugars (glycans) on proteins. Ours don’t - that’s the difference. Our platform detects multiple glycoform biomarkers in a single test, improving diagnostic accuracy and reducing false alarms. No new equipment, just hard science that works.
Proteomics Clinical Applications | July 2023
Serum/Plasma Proteomics | February 2023
Electrophoresis: Focus On Glycomics & Glycoproteomics | December 2011
What we’re building will change lives
Our ovarian cancer biomarkers are licensed from Queensland Institute for Medical Research (QIMR Berghofer), validated through peer-reviewed studies with leading universities and scientific agencies, and built to meet global regulatory standards.
8 million lives at risk by 2050 without early detection
4 years longer for women to receive diagnosis vs men, across many conditions
10x higher risk of ovarian cancer in women with endometriosis
No new reagents or equipment needed. Runs on clinical mass spectrometers
One platform from R&D to clinical test—no delays, no bottlenecks
Get the latest on our diagnostics
Receive clinical updates and diagnostic developments focused on early detection and women’s health.
Our supporters
